Rekombinanter RSV (Felvizumab Biosimilar) Antikörper

Produktnummer ABIN5668206

Produktdetails anti-RSV (Felvizumab Biosimilar) Antikörper

Target: RSV (Felvizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Respiratory Syncytial Virus (RSV)

Wirt: Human

Klonalität: Monoklonal

Konjugat: Dieser RSV (Felvizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: ELISA, Functional Studies (Func)

Spezifität: This antibody is specific for the conserved fusion (F) protein of RSV.

Produktmerkmale:

OriginalSpeciesName: Human

OriginalFormat: IgG1

Aufreinigung: Purified antibody.

Reinheit: > 98 % as determined by SDS-PAGE

Endotoxin-Niveau: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogen: This antibody was prepared by the humanization of an F protein-specific murine MAb, RSV19. More specifically, molecular techniques were used to insert the complementarity determining regions from murine RSV19 into a human IgG1 heavy and k light chain-variable domain framework.

Klon: RSHZ19

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Though shown to be safe and well-tolerated (Everitt, 1996) and protective against RSV infection in BALB/c mice and cotton rats (Wyde, 1995), this antibody did not demonstrate efficacy in a Phase 3 study (Reichert, 2008). In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999).

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Details zu RSV (Felvizumab Biosimilar)

Target: RSV (Felvizumab Biosimilar)

Abstract: RSV (Felvizumab Biosimilar) Produkte

Substanzklasse: Biosimilar

Hintergrund: SB 209763, respiratory syncytial virus